Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + n-acetylcysteine is a combination of two small molecule drugs, atorvastatin (a statin) and n-acetylcysteine (an antioxidant and mucolytic agent). This combination has been investigated primarily for its potential to prevent contrast-induced nephropathy in patients undergoing procedures such as percutaneous coronary intervention. Atorvastatin works by inhibiting HMG-CoA reductase, leading to reduced cholesterol synthesis and pleiotropic effects including anti-inflammatory actions. N-acetylcysteine acts as an antioxidant by replenishing intracellular glutathione stores and directly scavenging free radicals. The combination has shown synergistic effects in reducing oxidative stress, apoptosis, inflammation, and improving outcomes in models of kidney injury, immune thrombocytopenia resistant to steroids, and non-alcoholic fatty liver disease[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + n-acetylcysteine.